Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α

British Journal of Cancer

Volumn 102, Issue 10, 2010, Pages 1456-1460

  Yang, S ^a   De Souza, P ^b   Alemao, E ^a   Purvis, J ^a,c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Interferon; Quality of life; Renal cell carcinoma; Temsirolimus

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HEALTH STATUS; HUMANS; INTERFERON-GAMMA; KIDNEY NEOPLASMS; QUALITY OF LIFE; SIROLIMUS;

EID: 77952215842     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605647     Document Type: Article

References (29)

1. Brooks R (1996) EuroQol: the current state of play. Health Policy 37: 53-72
2. Brugarolas J (2007) Renal-cell carcinoma: molecular pathways and therapies. N Engl J Med 356: 185-187
3. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26: 3763-3769
4. Coppin C, Le L, Porzsolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 16: CD006017
5. de Boer AG, van Lanschot JJ, Stalmeier PF, van Sandick JW, Hulscher JB, de Haes JC, Sprangers MA (2004) Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res 13: 311-320
6. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35: 1095-1108
7. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, de Charro F (2003) A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 4: 222-231
8. Gueorguieva R, Krystal JH (2004) Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psych 61: 310-317
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281 (Pubitemid 46849157) (Pubitemid 46849157) (Pubitemid 46849157)
10. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
11. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ (2004) Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 13: 1247-1253
12. Littell RC, Henry PR, Ammerman CB (1998) Statistical analysis of repeated measures data using SAS procedures. J Anim Sci 76: 1216-1231
13. Mathew A, Devesa SS, Fraumeni Jr JF, Chow WH (2002) Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11: 171-178
14. Mekhail TM, Abou-Jawde RM, BouMerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23: 832-841
15. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296
16. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
18. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540
19. National Cancer Institute (2006) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf Accessed October 12, 2009
20. National Institutes of Health (2007) Study evaluating interferon and CCI-779 in advanced renal cell carcinoma. [updated 2007 Dec 19; cited 2009 July 18] http://www.clinicaltrials.gov/ct2/show/NCT00065468?term=cci+779&rank=12 Accessed October 12, 2009.
21. Oppe M, Rabin R, de Charro F (2008) EQ-5D User Guide. Version 1.0 The EuroQol Group: Rotterdam, The Netherlands
22. Pickard AS, Neary MP, Cella D (2007) Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5: 70
23. Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA (2007) Interpreting clinically significant changes in patient-reported outcomes. Cancer 110: 196-202
24. Roferon-A (interferon alfa-2a, recombinant) (2008) US Full Prescribing Information. Hoffman-La Roche: Nutley, NJ, USA http//www.rocheusa.com/products/ roferon/pi.pdf Accessed October 12, 2009.
25. The EuroQol Group (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16: 199-208
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
27. van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16: 709-717
28. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (2007) Campbell-Walsh Urology. 9th edn. Saunders Elsevier: PA, USA
29. Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S (2010) Q-TWiST analysis of patients receiving temsiro-limus or interferon alfa for treatment of advanced renal cell carcinoma. Pharmacoeconomics 7, e-pub ahead of print 14 June 2010